CLAIMS

1. ~~Pidotimod~~ The use of pidotimod or a physiologically acceptable salt thereof, ~~for use~~ in the manufacture of a medicament for the treatment of irritable bowel syndrome.
2. ~~Pidotimod or a physiologically acceptable salt thereof for~~ The use according to claim 1, characterized in that said irritable bowel syndrome is in form of IBS-D, IBS-C or IBS-A.
3. ~~Pidotimod or a physiologically acceptable salt thereof for~~ The use according to claim 1, characterized in that ~~it~~ the medicament is to be administered to a human.
4. ~~Pidotimod or a physiologically acceptable salt thereof for~~The use according to claim 1, characterized in that ~~it~~ the medicament is to be administered orally.
5. ~~Pidotimod or a physiologically acceptable salt thereof for~~The use according to claim 4, characterized in that ~~it~~ the medicament is to be administered by means of a solid or liquid formulation.
6. ~~Pidotimod or a physiologically acceptable salt thereof for~~The use according to claim 5, characterized in that said solid formulation is a tablet, a film-coated tablet, a capsule, a dragée or a sachet.
7. ~~Pidotimod or a physiologically acceptable salt thereof for~~The use according to claim 5, characterized in that said liquid formulation is a solution or a suspension.
8. ~~Pidotimod or a physiologically acceptable salt thereof for~~The use according to claim 5, characterized in that said solid formulation has a w/w concentration in pidotimod from 50% to 90%, more preferably from 65% to 80%, most preferably from 70% to 75%.

9. ~~Pidotimod or a physiologically acceptable salt thereof for~~The use according to claim 5, characterized in that said liquid formulation has a w/w concentration in pidotimod from 0.5% to 20%, more preferably from 1% to 10%, most preferably from 2% to 8%.

10. ~~Pidotimod or a physiologically acceptable salt thereof for~~The use according to claim 5, characterized in that said formulation has a content in pidotimod or a salt thereof, from 10 to 1000 mg per single dose, preferably from 50 to 800 mg per single dose.

11. ~~Pidotimod or a physiologically acceptable salt thereof for~~The use according to claim 1, characterized in that ~~it~~ the medicament is to be administered rectally.

12. ~~Pidotimod or a physiologically acceptable salt thereof for~~The use according to claim 11, characterized in that ~~it~~ the medicament is to be administered by means of a semi-solid or liquid formulation.

13. ~~Pidotimod or a physiologically acceptable salt thereof for~~The use according to claim 12, characterized in that semi-solid formulation is a suppository, a cream, a gel, an ointment or an emulsion.

14. ~~Pidotimod or a physiologically acceptable salt thereof for~~The use according to claim 12, characterized in that said liquid formulation is a solution or a suspension.

15. ~~Pidotimod or a physiologically acceptable salt thereof for~~The use according to claim 12, characterized in that said formulation has a w/w concentration in pidotimod or a salt thereof from 0.1% to 20%, preferably from 1% to 15%, more preferably from 5% to 10%.

16. ~~Pidotimod or a physiologically acceptable salt thereof for~~The use according to any of the preceding claims, characterized in that ~~it~~ the medicament is to be

administered in combination or in temporal proximity with at least one additional active principle.

17. ~~Pidotimod or a physiologically acceptable salt thereof for~~The use according to claim 16, characterized in that said at least one additional active principle is selected from tricyclic antidepressants, antibiotics, 5-HT3 antagonists and/or guanylate cyclase-C agonists, dietary fibers, probiotics.

18. ~~Pidotimod or a physiologically acceptable salt thereof for~~The use according to claim 17, characterized in that said at least one tricyclic antidepressants is selected from amitriptyline, clomipramine, imipramine, nortryptiline.

19. ~~Pidotimod or a physiologically acceptable salt thereof for~~The use according to claim 17, characterized in that said at least one antibiotic is selected from rifaximin, neomycin, kanamycin, gentamicin, amikacin, streptomycin, other aminoglycosides and in general antibiotics which are not absorbed by the intestinal tract.

20. ~~Pidotimod or a physiologically acceptable salt thereof for~~The use according to claim 17, characterized in that said at least one 5-HT3 antagonists is alosetron.

21. ~~Pidotimod or a physiologically acceptable salt thereof for~~The use according to claim 17, characterized in that said at least one guanylate cyclase-C agonists is linaclotide.

22. ~~Pidotimod or a physiologically acceptable salt thereof for~~The use according to claim 17, characterized in that said at least one probiotic include one form the group of *Bifidobacterium* spp. and *Lactobacillus* spp.